![](/sites/default/files/Mosaic_def.png)
10 . 06 .2022
Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)
![](/sites/default/files/Mosaic_def.png)
08 . 06 .2022
Press release
Galderma to present new findings from innovative product portfolio at the 2022 VCS Annual Symposium
![](/sites/default/files/Mosaic_def.png)
02 . 06 .2022
Press release
Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
![](/sites/default/files/TOP%20IMAGE.png)
01 . 06 .2022
News story
Actinic Keratosis prevention campaign encourages everyone to ‘FACE THE FACTS’
![](/sites/default/files/Mosaic_def.png)
31 . 05 .2022
Press release
Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022
![](/sites/default/files/Mosaic_def.png)
25 . 04 .2022
Press release
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
04 . 04 .2022
Press release
Galderma launches a virtual experience this Rosacea Awareness Month showcasing how the condition goes beyond the visible with Rosacea Space
28 . 03 .2022
Press release
Galderma to present new clinical data and high patient satisfaction across their portfolio of dermal fillers, collagen biostimulators and liquid neuromodulators at AMWC 2022
25 . 03 .2022
Press release
Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting